IL127739A0 - Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases - Google Patents

Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases

Info

Publication number
IL127739A0
IL127739A0 IL12773997A IL12773997A IL127739A0 IL 127739 A0 IL127739 A0 IL 127739A0 IL 12773997 A IL12773997 A IL 12773997A IL 12773997 A IL12773997 A IL 12773997A IL 127739 A0 IL127739 A0 IL 127739A0
Authority
IL
Israel
Prior art keywords
retinoyloxy
butyrates
alkylene
cancer
substituted
Prior art date
Application number
IL12773997A
Other languages
English (en)
Original Assignee
Bar Illan University
Kupat Holim Health Insurance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,481 external-priority patent/US6040342A/en
Priority claimed from US08/883,219 external-priority patent/US6071923A/en
Application filed by Bar Illan University, Kupat Holim Health Insurance filed Critical Bar Illan University
Publication of IL127739A0 publication Critical patent/IL127739A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12773997A 1996-07-02 1997-07-01 Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases IL127739A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/674,481 US6040342A (en) 1994-09-16 1996-07-02 Retinoyloxy (alkyl-substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
US08/883,219 US6071923A (en) 1994-09-16 1997-06-26 Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
PCT/US1997/011452 WO1998000127A1 (en) 1996-07-02 1997-07-01 Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases

Publications (1)

Publication Number Publication Date
IL127739A0 true IL127739A0 (en) 1999-10-28

Family

ID=27101163

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12773997A IL127739A0 (en) 1996-07-02 1997-07-01 Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases

Country Status (6)

Country Link
EP (1) EP0927033A1 (enExample)
JP (1) JP2002514161A (enExample)
AU (1) AU3588097A (enExample)
CA (1) CA2258593A1 (enExample)
IL (1) IL127739A0 (enExample)
WO (1) WO1998000127A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6110970A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体－细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
HK1038881A1 (zh) * 1998-04-17 2002-04-04 利思进药品公司 通过共同给予前列腺素抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US6720445B2 (en) 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
SE0101702D0 (sv) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
WO2005092283A1 (en) 2004-03-26 2005-10-06 Dsm Ip Assets B.V. Composition comprising an hdac inhibitor in combination with a retinoid
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677120A (en) * 1985-07-31 1987-06-30 Molecular Design International Topical prodrugs for treatment of acne and skin diseases
DK498487A (da) * 1986-10-06 1988-04-07 Hoffmann La Roche Hidtil ukendte retinoider
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
US4885311A (en) * 1987-06-29 1989-12-05 Molecular Design International Topical transretinoids for treatment of acne and skin diseases
CA2037150C (en) * 1990-03-27 1999-12-28 Guenter Gross Retinoids
US5710176A (en) * 1994-09-16 1998-01-20 Bar-Ilan University Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases

Also Published As

Publication number Publication date
JP2002514161A (ja) 2002-05-14
EP0927033A1 (en) 1999-07-07
AU3588097A (en) 1998-01-21
WO1998000127A1 (en) 1998-01-08
CA2258593A1 (en) 1998-01-08
EP0927033A4 (enExample) 1999-07-07

Similar Documents

Publication Publication Date Title
ZA957483B (en) Compounds and methods for the treatment of cancer
IL129352A0 (en) Benzimidazole-2- carbamates for the treatment of viral infections and cancer
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
EP0764030A4 (en) USE OF AUTOANTIBODIES FOR ANTI-TUMOR THERAPY AND PROPHYLAXIS
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
EP0942742A4 (en) THERAPEUTIC COMPOSITIONS FOR CANCER TREATMENT
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
AU1980995A (en) Methods and compositions for treatment of breast cancer
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
IL101410A0 (en) Formulation for the treatment of cancer
ZA954984B (en) Compositions and methods for the treatment of tumors
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
AU7770991A (en) Method and composition for the treatment of cancer
MD798F1 (en) Method of the mamma cancer treatment
EP0733365A3 (en) Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer
GB9510162D0 (en) Compositions for the treatment of skin conditions
AU8809098A (en) Procedure and apparatus for the treatment of waste
AU5754996A (en) Agent for the treatment of radiation injuries
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
GB2312375B (en) Agents for treatment of cancer
AU4825993A (en) New compounds for use in the treatment of cancer